262 related articles for article (PubMed ID: 16722544)
1. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications.
Zimmermann M; Zouhair A; Azria D; Ozsahin M
Radiat Oncol; 2006 May; 1():11. PubMed ID: 16722544
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
3. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
Burtness B
Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
[TBL] [Abstract][Full Text] [Related]
4. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells.
Rubin Grandis J; Chakraborty A; Melhem MF; Zeng Q; Tweardy DJ
Oncogene; 1997 Jul; 15(4):409-16. PubMed ID: 9242377
[TBL] [Abstract][Full Text] [Related]
6. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
7. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
8. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines.
Oshima G; Wennerberg J; Yamatodani T; Kjellén E; Mineta H; Johnsson A; Ekblad L
J Cancer Res Clin Oncol; 2012 Mar; 138(3):491-9. PubMed ID: 22193422
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor directed therapy in head and neck cancer.
Choong NW; Cohen EE
Crit Rev Oncol Hematol; 2006 Jan; 57(1):25-43. PubMed ID: 16207530
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor alpha stimulation of mucosal tissue cultures from head and neck squamous cell carcinoma patients increases chemoresistance to cisplatin.
Baumeister P; Reiter M; Schwenk-Zieger S; Harréus U
Chemotherapy; 2010; 56(4):268-74. PubMed ID: 20693797
[TBL] [Abstract][Full Text] [Related]
12. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer.
Kim S; Grandis JR; Rinaldo A; Takes RP; Ferlito A
Head Neck; 2008 May; 30(5):667-74. PubMed ID: 18383530
[TBL] [Abstract][Full Text] [Related]
13. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
14. The epidermal growth factor receptor as a target for colorectal cancer therapy.
Lockhart AC; Berlin JD
Semin Oncol; 2005 Feb; 32(1):52-60. PubMed ID: 15726506
[TBL] [Abstract][Full Text] [Related]
15. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
16. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Yonesaka K; Zejnullahu K; Lindeman N; Homes AJ; Jackman DM; Zhao F; Rogers AM; Johnson BE; Jänne PA
Clin Cancer Res; 2008 Nov; 14(21):6963-73. PubMed ID: 18980991
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.
Ang KK; Andratschke NH; Milas L
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456
[TBL] [Abstract][Full Text] [Related]
18. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Brockstein B; Lacouture M; Agulnik M
J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
[TBL] [Abstract][Full Text] [Related]
19. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
